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The risk of febrile neutropenia in patients with non-small-cell lung
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We aimed to assess the incidence of febrile neutropenia in patients with non small cell lung cancer treated with docetaxel as second
line chemotherapy by systematic review and meta-analysis of clinical studies. Published studies were retrieved and included if they
considered docetaxel at the licensed dose after a previous chemotherapy regimen, and reported the proportion of patients getting
FN. Meta-analysis was conducted to estimate the proportion of patients who experience one or more episodes of FN. The pooled,
random effects meta-analysis estimate for the proportion of patients who experience one or more episodes of FN on docetaxel was
5.95% (95% CI 4.22–8.31) based on 13 studies, comprising 1609 patients. No significant differences were seen either between
studies that permitted the use of prophylactic granulocyte colony-stimulating factors or between phase II and phase III trials.
Evidence from randomised controlled trials suggests that the incidence of FN with docetaxel is around 6% and therefore an
important factor to consider in the choice of the chemotherapy regimen.
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Chemotherapy-induced febrile neutropenia (FN) is a serious
adverse event caused by cancer therapies that can have a
significant impact on mortality, morbidity and health care costs.
FN impacts on quality of life both directly and indirectly, because
it may lead to serious and potentially fatal infections and also
because chemotherapy treatments can only be delayed or reduced
with potentially detrimental clinical consequences . In addition,
patients almost always require hospitalisation and treatment with
antibiotics.
To reduce the risk of FN, recombinant human granulocyte
colony-stimulating factors (G-CSFs) or granulocyte –macrophage
colony-stimulating factors (GM-CSFs) may be considered. These
agents can be used to prevent FN in all patients receiving
chemotherapy, but they are costly. Consequently, they have been
recommended for use in treating and preventing FN only in high-
risk patients (Aapro et al, 2006; NCCN, 2006; Smith et al, 2006), in
whom the evidence for their effectiveness is strongest. Antibiotic
prophylaxis is an alternative prevention strategy that has been
considered in several studies, although concerns about widespread
antibiotic resistance have limited the use of this strategy in practice
(NCCN, 2006).
In considering alternative preventative strategies, the differential
risks, costs and potential benefits must be weighed up. Therefore,
it is essential to accurately identify the risk of FN associated with
any particular chemotherapy regimen. The European Organisation
for Research and Treatment of Cancer guidelines (Aapro et al,
2006) and American Society of Clinical Oncology guidelines (Smith
et al, 2006) both state that where the risk of FN with a
chemotherapy is in excess of 20%, G-CSF prophylaxis is
recommended in that patient group, and that where the risk
associated with a specific regimen is lower than 20% there should
be consideration of other patient factors such as age and co-
morbidities.
Yet information on the risk of FN is lacking in this area. In
patients with non-small-cell lung cancer (NSCLC), three second-
line treatments are currently licensed in Europe: pemetrexed
(Alimtas, Eli Lilly and Company, Indianapolis, USA), docetaxel
(Taxoteres, Sanofi-Aventis, Paris, France) and erlotinib (Tarcevas,
Roche, Basel, Switzerland). Pemetrexed is rarely used in practice.
In the UK National Health Service (NHS), pemetrexed is not
recommended for use in this patient group by the National
Institute for Health and Clinical Excellence (NICE, 2007a). On the
other hand, docetaxel is widely used in practice and is
recommended by NICE (NCCAC, 2005). A third treatment,
erlotinib, is a newer oral treatment that has been the subject of a
recent NICE appraisal. As a part of that appraisal, the cost
effectiveness of erlotinib compared with docetaxel was estimated.
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Table 1 Characteristics of included studies
Characteristics of trial patients on docetaxel 75 mg m2
Study Interventions
Age median
(range)
Tumour stage
N (%)
Performance status
ECOG n (%) G-CSF use FN n (%)
Camps et al (2006)
Spain
Docetaxel 75 mg m2 one infusion every 3 weeks, n¼ 131, vs
docetaxel 36 mg m2 one infusion every week for 6 weeks
followed by 2-week rest, n¼ 128. Treatment continued until
disease progression or unacceptable toxicity.
61 (36–80)
IIIB 19 (14.8)
IV 107 (82.9)a
0 31 (24)
1 77 (59.7)
2 21 (16.3)
10/129 (7.8)
Chen et al (2006)
Taipei
Docetaxel 35 mg m2 i.v. infusion on days 1, 8 and 15 every 4
weeks, n¼ 64, vs docetaxel, 40 mg m2 i.v. on days 1 and 8
every 3 weeks, n¼ 64, vs docetaxel, 75 mg m2 every 3 weeks,
n¼ 33. Treatment continued until disease progression or
unacceptable toxicity.
64 (34–83)
IIIB 3 (9.1)
IV 30 (90.9)
0 0
1 13 (39.4)
2 20 (60.6)
Used as treatment
for all patients with
FN, n¼ 4 (12.1%)
4/33 (12.1)
Cufer et al (2006)
International
Gefitinib oral dose of 250 mg per day, n¼ 68, vs i.v. docetaxel
75 mg m2 per day on day 1 every 3 weeks, n¼ 73. Treatment
continued until disease progression or unacceptable toxicity.
59.5 (29–83)
IIIB not reportedb
IV 41 (56.2)
0 11 (15.1)
1 41 (56.2)
2 21 (28.8)
2/63 (3.2)
Fossella et al (2000)
USA
Docetaxel 100 mg m2 one infusion every 3 weeks, n¼ 125, vs
docetaxel 75 mg m2 one infusion every 3 weeks, n¼ 125, vs
vinorelbine on days 1,8 and 15 of every 3-week cycle or
ifosfamide on days 1–3 of every 3-week cycle, n¼ 123.
Treatment continued after six cycles if condition satisfactory.
59 (not
reported)
III not reported
IV 113 (90)c
0 not reportedd
1 not reported
2 23 (18)
Prophylactic or
therapeutic use in
7% of patients
NR/121 (8)
Gervais et al (2005)
France
Docetaxel 75 mg m2 one infusion every 3 weeks, n¼ 62, vs
docetaxel 40 mg m2 weekly for 6 weeks and a 2-week rest,
n¼ 63. Treatment continued until disease progression or
unacceptable toxicity.
59 (37–72.5)
IIIB 21 (34)
IV 41 (66)
0 9 (15)
1 40 (65)
2 13 (21)
4/62 (6.5)
Gridelli et al (2004)
Italy
Docetaxel 75 mg m2 one infusion every 3 weeks for six cycles,
n¼ 110, vs docetaxel 33.3 mg m2 on days 1, 8, 15, 22, 29 and
36 every 8 weeks (6 weeks of treatment followed by 2 weeks
of rest) for two cycles, n¼ 110. Further therapy was
discretional.
62 (26–74)
IIIB 21 (19)
IV 89 (81)
0 35 (32)
1 58 (53)
2 17 (15)
NR/110 (5)
Hanna et al (2004)
USA
Pemetrexed 500 mg m2 as an infusion, n¼ 283, vs docetaxel
75 mg m2 as an infusion, n¼ 288, on day 1 of a 21-day cycle.
Treatment continued until disease progression or unacceptable
toxicity.
57 (28–87)
III not reported
IV 215 (74.7)e
0 or 1 252 (87.6)
2 36 (12.4)
Prophylactic use in
4 (1.4%) patients
and as treatment in
49 (17%) patients
NR/126 (12.7)
Pectasides et al (2005)
Greece
Docetaxel 75 mg m2 one infusion every 3 weeks, n¼ 65, vs
docetaxel 30 mg m2 (1-h infusion) and irinotecan 60 mg m2
(90-min infusion) on days 1 and 8, both administered every 3
weeks, n¼ 65. Treatment continued until disease progression
or unacceptable toxicity.
59 (38–76)
Disease stage not
reported
0 20 (31)
1 37 (57)
2 8 (12)
Therapeutic or
prophylactic use in
18 (28%) patients
3/65 (4.6)
Quoix et al (2004)
France
Docetaxel 100 mg m2 one infusion every 3 weeks, n¼ 89, vs
docetaxel 75 mg m2 one infusion every 3 weeks, n¼ 93. Study
planned for six cycles and further treatment could be given at
physician’s discretion.
59.0 (36.0–74.2)
I 5 (5.4)
II 2 (2.1)
III 8 (8.6)
IIIB 20 (21.5)
IV 58 (62.4)
0 16 (17.2)
1 53 (57.0)
2 24 (25.8)
6/89 (6.7)
Ramlau et al (2006)
International
Oral topotecan 2.3 mg m2 per day on days 1–5, n¼ 414, vs
i.v. docetaxel 75 mg m2 per day on day 1 every 3 weeks,
n¼ 415, for at least four cycles. Additional cycles permitted.
58.7 (24–82)
III 117 (28)
IV 298 (72)
0 76 (18)
1 273 (66)
2 65 (16)
4 1 (o1)
Administered to 30
(8%) patients
11/401 (2.7)
Schuette et al (2005)
Germany
Docetaxel 75 mg m2 one infusion every 3 weeks, n¼ 103, vs
docetaxel 35 mg m2 on days 1, 8 and 15 of a 28-day cycle,
n¼ 105. Patients to receive a maximum of eight cycles of their
regime.
63 (42–80)
IIIB not reported
IV not reportedf
0 34 (33.0)
1 55 (53.4)
2 12 (11.7)
Non-assessable
2 (1.9)
Used at physician’s
discretion. No data
on actual use
reported
2/102 (2.0)
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Clinical Studies
As erlotinib does not have haematological toxicity, a crucially
important component of the cost effectiveness estimate is the
probability of FN in patients treated with docetaxel. Results are
particularly sensitive to this probability (DSU, 2007) yet data on
this parameter proved controversial (NICE, 2007b). The European
Organisation for Research and Treatment of Cancer cite percen-
tages of patients experiencing one or more episodes of FN of 26%
for docetaxel in combination with carboplatin, and between 5 and
11% in combination with cisplastin. However, these estimates are
based on only a small number of studies of varying quality, and as
much of the evidence relates to first-line treatments, they may not
be applicable for second-line NSCLC patients. The American
Society of Clinical Oncology guidelines report that 12.7% of
second-line NSCLC patients experienced FN but this is based on a
single study (Hanna et al, 2004). We therefore conducted a
systematic review and meta-analysis of docetaxel studies in NSCLC
to identify the risk of FN, specifically for these patients.
METHODS
Search strategy
A comprehensive search was undertaken to identify the literature
on docetaxel use in NSCLC. The databases searched (for all years
that were indexed) were Medline, Medline in Process, EMBASE
and The Cochrane Library, including the Cochrane Database of
Systematic Reviews, Cochrane Controlled Trials Register (CEN-
TRAL), DARE, NHS EED and HTA databases. Searches were not
restricted by language or publication type. The search strategy for
EMBASE was modified to include additional terms around
‘Neutropenia’, as omitting these terms resulted in an unmanage-
able result set of limited specificity.
Earlier systematic reviews considering docetaxel were also
considered so that a manual search of their reference lists could
be conducted to ensure that all relevant studies had been
identified. Studies that met the inclusion criteria mentioned above
but were only published as abstracts or as conference presenta-
tions were not included in the review unless a full paper could be
obtained that related to the abstract.
Inclusion criteria
Studies were included if they assessed the use of docetaxel as
monotherapy at the standard recommended dose (75 mg m2 as a
1-h infusion every 3 weeks), in patients with NSCLC who had
received one or more previous chemotherapy regimens for their
disease and for which FN events were reported.
Data extraction
The primary outcome of the review was the rate of one or more
episodes of FN among patients receiving docetaxel. We also sought
to extract information on the grade of neutropenia and the
proportion of patients receiving either G-CSFs or antibiotics to
prevent or treat FN in those studies. Additional information
regarding the baseline characteristics of the patient populations
who took part in the studies and description of survival outcomes
and treatment duration were also extracted and were reported.
Evidence synthesis
Meta-analysis was performed on the log odds scale and results
were transformed back to the proportion scale for interpretation.
Heterogeneity between the studies was assessed using the
I2 statistic and where it was greater than 0, a random effect
meta-analysis model was used in preference over a fixed effect one.
Where heterogeneity existed covariates were included in the
analysis in an attempt to explain the between-study heterogeneity.T
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RESULTS
A total of 950 studies were identified from the literature searches.
Titles and abstracts were scanned for relevance and full copies of
40 studies were ordered. Of these, 13 studies were selected for
inclusion, eight of which were phase III randomised controlled
trials (RCTs) (Fossella et al, 2000; Shepherd et al, 2000; Gridelli
et al, 2004; Hanna et al, 2004; Schuette et al, 2005; Camps et al,
2006; Chen et al, 2006; Ramlau et al, 2006) and five were phase II
RCTs (Quoix et al, 2004; Gervais et al, 2005; Pectasides et al, 2005;
Wachters et al, 2005; Cufer et al, 2006). The relevant data were
contained in single trial arms, which consisted of a total of 1609
patients (see Table 1). The comparators to standard dose docetaxel
included different doses of docetaxel, best supportive care or other
active treatments (irinotecan, topotecan, vinorelbine, ifosfamide,
gefitinib or pemetrexed).
All studies report a mean patient age of around 60 years with a
range of between the mid-30s and mid-70s in most studies. All
patients have advanced NSCLC with the majority having metastatic
disease (stage IV). The majority of patients in the trials have,
however, good performance status (0 or 1); that is, they are
ambulatory and are able to carry out work of a light or sedentary
nature with few restrictions.
Seven of the 13 studies included described some use of G-CSF in
their study patients (Table 1). Only one of these reported
prophylactic use of G-CSF in all study patients (Wachters et al,
2005). The remainder reported that a minority of study patients
received G-CSF. Two studies reported data separately for the
proportions of patients receiving G-CSF for prophylaxis: 1.4%
(Hanna et al, 2004), and for treatment of FN: 17% (Chen et al,
2006) and 12.1% (Hanna et al, 2004). Two studies reported
combined prophylactic and treatment use of G-CSF: 28% (Pecta-
sides et al, 2005) and 8% (Ramlau et al, 2006). One study reported
that G-CSFs were used in 7% of cycles either prophylactically or as
treatment for FN (Fossella et al, 2000) and one study simply
reported that G-CSFs were used at the physician’s discretion
without providing actual data (Schuette et al, 2005).
In all trials FN events are presented as the percentage of patients
experiencing one or more episode of FN. The final column of
Table 1 summarises these percentages for the arms of the studies,
in which the standard doses of docetaxel were administered; that
is, 75 mg m2 given intravenously over 1 h every 3 weeks. The trials
do not generally report the number of events per person and
almost all studies combined the grades of FN together. In studies
that did not prescribe G-CSFs, FN rates for patients treated with
the recommended standard dose of docetaxel ranged from 1.8 to
7.8%. In studies that prescribed G-CSFs, FN rates ranged from 2.0
to 12.7%. None of the studies reported using prophylactic
antibiotics.
Meta-analysis
Meta-analysis was conducted on the 13 study arms described in
Table 1. Some numerator data for the percentage of patients with
FN were not reported but these were derived directly using the
denominators and percentages reported in the papers. Only one
figure was equivocal – the numerator for Gridelli et al (2004) – as
five or six events would provide a percentage rounding up or down
to 5%. Six events were imputed in this instance. Hence the data
used in the meta-analysis are provided in Figure 1.
Owing to between-study heterogeneity (I2¼ 52.9%), a random
effect meta-analysis was conducted. The pooled, random effects
meta-analysis estimate for the proportion of patients who
Note: Weights are from random effects analysis
Heterogeneity between groups: P = 0.681
Overall  (I2 = 52.9%, P = 0.013)
Ramlau19
G-CSFs used
Subtotal  (I2 = 72.8%, P = 0.001)
Camps2
Pactasides17
Hanna10
Schuette20
Chen3
Subtotal  (I2 = 0.0%, P = 0.666)
Wachters 2005
Quoix18
Gridelli9
Gervais8
Shepherd21
Cufer4
No G-CSFs used
Fossella7
Study
100.00
11.15
57.39
10.63
6.05
12.01
4.70
6.85
42.61
6.02
8.71
8.76
7.09
2.76
4.66
10.61
Weight
%
11
10
3
16
2
4
3
6
6
4
1
2
10
Events
401
129
65
126
102
33
56
89
110
62
55
63
121
Total
2.7 (1.5 to 4.9)
7.7 (4.2 to 13.8)
4.6 (1.5 to 13.4)
12.7 (7.9 to 19.7)
2.0 (0.5 to 7.5)
12.1 (4.6 to 28.2)
5.4 (1.7 to 15.3)
6.7 (3.1 to 14.2)
5.5 (2.5 to 11.6)
6.5 (2.4 to 16.0)
1.8 (0.3 to 11.8)
3.2 (0.8 to 11.8)
8.3 (4.5 to 14.7)
Percent (95% CI)
2510521
Percentage with FN (log scale)
6.1 (4.3 to 8.6) 
6.0 (3.4 to 10.5)
6.0 (4.2 to 8.3)
Figure 1 Forest plot for ln (odds) of experiencing FN on standard dose docetaxel (75 mg m2 given intravenously once every 3 weeks).
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experience one or more episodes of FN on docetaxel is 5.95% (95%
CI 4.22– 8.31). We conducted a subgroup analysis comparing
studies that reported any G-CSF use with those that did not report
use of G-CSFs as well as an overall analysis (Figure 1). For studies
in which no G-CSF use was reported, the proportion of patients
experiencing FN was 6.07% (95% CI 4.27–8.63) compared with
6.01% (95% CI 3.36–8.32) for studies in which G-CSF use was
reportedly permitted. Although effect sizes in both groups were
almost identical, the majority of the observed heterogeneity was in
the group, which had some G-CSF use (I2¼ 72.8 and 0% for G-CSF
and non-G-CSF groups, respectively).
A further subgroup analysis was carried out combining phase III
and phase II trials separately. Pooled estimates were similar from
both (phase II¼ 5.54% (3.52–8.62) and phase III¼ 6.08% (3.68–
9.87)) with the majority of the heterogeneity being observed in the
phase III studies (I2¼ 70.6% for phase III and 0% for phase II).
DISCUSSION
The meta-analysis results show that the incidence of FN associated
with docetaxel as second-line therapy in trial patients with
advanced NSCLC is approximately 6%. Individual patients and
clinicians will want to consider this information as one element of
the risks and benefits associated with alternative available
chemotherapy regimens, which must be weighed up. Similarly, in
deciding whether FN prophylaxis, such as antibiotics or G-CSFs,
are appropriate for patients receiving docetaxel, the risk associated
with the chemotherapy regimen must be considered alongside the
risk factors related to the individual patient (for example, age,
performance status) and the underlying disease. In relation to
current European and American guidelines on the use of G-CSFs,
the incidence of FN with docetaxel in NSCLC is relatively low.
This information is also a critical factor in policy-level decisions,
such as those made by NICE, when considering the effectiveness
and cost-effectiveness of available alternatives. In instances in
which the figures for FN calculated in this report are used in
assessing the cost effectiveness of erlotinib compared with
docetaxel, it is considered unlikely that erlotinib is a cost-effective
treatment (NICE, 2008), although this conclusion is obviously
dependent on many other factors, including the price of erlotinib.
It is important to note that in routine practice, FN rates might be
different, as the clinical trial participants, although potentially
more likely to have advanced disease, are often younger and have
better performance status than those who do not choose to
participate (Elting et al, 2006). In addition, the FN rates reported in
this review are those associated with licensed use of docetaxel; that
is, 75 mg m2. FN rates associated with larger doses of docetaxel,
for example, 100 mg m2, tend to be higher: 12 vs 8% (Fossella
et al, 2000) and 22.4 vs 1.8% (Shepherd et al, 2000), for 100 and
75 mg doses, respectively.
These estimates may be limited by the reporting of G-CSF use
within the trials and the necessity to categorise studies somewhat
crudely as either using G-CSFs or not. The analysis does not
consider the proportion of patients being administered G-CSF
within studies. It is perhaps surprising that no specific observa-
tional studies were identified for this review, although such studies
would be appropriate to improve the evidence base and would also
allow factors that can be obscured in multi-national trials to be
addressed. For example, the degree of clinical experience in using
docetaxel, as with any chemotherapy regimen, is likely to be an
important factor in achieving good patient management of which
low rates of FN would be considered an important element. For
these reasons, future observational studies could add to this meta-
analysis and allow health system-specific issues to be considered.
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Appendix 1
Search terms
A comprehensive search was undertaken to identify literature on
docetaxel use in Lung cancer. The search strategy for EMBASE was
modified to include additional terms around ‘Neutropenia’ as
omitting these terms resulted in an unmanageable result set of
limited specificity. Searches were not restricted by language,
publication date or publication type. Databases searched were
Medline, Medline in Process, EMBASE and The Cochrane Library,
including the Cochrane Database of Systematic Reviews, Cochrane
Controlled Trials Register (CENTRAL), DARE, NHS EED and HTA
databases.
Search strategy for Medline and Cochrane Databases
(1) Carcinoma, Non-Small-Cell Lung/
(2) Lung neoplasms/
(3) docetax?l.tw.
(4) docetax?l.rn.
(5) docetax?l.nm.
(6) taxotere.mp.
(7) 1 or 2
(8) or/3– 6
(9) 7 and 8
Search strategy for EMBASE
(1) Lung non Small Cell Cancer/
(2) Lung cancer/
(3) docetax?l.tw.
(4) docetax?l.rn.
(5) docetax?l.nm.
(6) taxotere.mp.
(7) 1 or 2
(8) or/3– 6
(9) 7 and 8
(10)neutropen$.tw.
(11)neutropaen$.tw.
(12)9 and 12
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